Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11229467 | 0.94 | ALDH1A1 (0.59) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL10012426 | 0.86 | — | — | |
| SCHEMBL10904416 | 0.85 | NR1I2 (0.68) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL1228244 | 0.85 | NR1I2 (0.68) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL10902814 | 0.85 | NR1I2 (0.68) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL11330132 | 0.84 | NR1I2 (0.79) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL11330152 | 0.84 | NR1I2 (0.79) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL3964566 | 0.83 | NR1I2 (0.59) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL10405954 | 0.83 | NR1I2 (0.59) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL28089696 | 0.82 | CYP1A2 (0.61) | NR1I2PGRADORA3PTGS2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883931-A1 | HETEROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Fondazione Telethon (IT) | 2021-09-29 | — | — | EP | disclosed |
| US-9130244-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2908376-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| CN-104795595-A | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES | 2015-07-22 | — | — | CN | disclosed |
| CN-102498605-B | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES | 2015-05-20 | — | — | CN | disclosed |
| EP-2479831-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| CN-102498605-A | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES | 2012-06-13 | — | — | CN | disclosed |
| CN-1034498-C | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO CO (JP) | 1997-04-09 | — | — | CN | disclosed |
| US-5604256-A | (7-(5-(1,3-DIOXANE-5YL)METHOXYIMINO-2-METHYL-8-(2-METHYLBUTYR -OXY)3-OXO-1,2,3,5,6,7,8,8A-OCTAHYDRO-1-NAPHTHYL)-3-HYDROXY-5 -OXOHEPTANOIC ACID AND SALTS | SANKYO COMPANY, LIMITED (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0570245-B1 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO CO (JP) | 1996-10-30 | — | — | EP | disclosed |
| CN-1084162-A | Be used to suppress the biosynthetic octahydronaphthalene oxime derivative of cholesterol, Preparation Method And The Use | SANKYO CO (JP) | 1994-03-23 | — | — | CN | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | SLC8A1, OR10J3, SLC8B1 | NR1I2 3345/4885PGR 3772/4885ADORA3 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.